B-type natriuretic peptide in pediatrics

Davis, Gershwin; Bamforth, Fiona; Sarpal, Amrita; Dicke, Frank; Rabi, Yacov; Lyon, Martha E.

doi:10.1016/j.clinbiochem.2005.12.004

Cited by 32 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies outside the scope of the systematic review have identified other factors associated with BNP and NT-proBNP such as hemodialysis, sepsis, surgery, liver cirrhosis, pneumonia and amyloidosis [76]. Furthermore, in the neonatal [77] and pediatric [78] populations, the utility of BNP and NT-proBNP may be different (e.g., management of ductus arteriosus in neonates), and the importance of various factors may be different compared to adults.…”

Section: Discussionmentioning

confidence: 91%

Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP

Balion

Santaguida

McKelvie

et al. 2008

Clinical Biochemistry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP

Balion

Santaguida

McKelvie

et al. 2008

Clinical Biochemistry

View full text Add to dashboard Cite

“…Consequently, clinical laboratory accreditation organizations and licensing agencies require that each laboratory verifies or establishes reference intervals for each method. A recent series of gap analyses of reference intervals available for various pediatric disease biomarkers [7][8][9][10][11] revealed major gaps in the available pediatric reference intervals, largely due to less than optimum number of subjects studied and obtained with older methodologies [12][13][14]. The current routine practice of applying reference intervals obtained on older methodologies/instruments to interpret results obtained on current methods and platforms is clearly questionable and likely contributes to erroneous interpretation and diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Canadian Laboratory Initiative on Pediatric Reference Interval Database (CALIPER): Pediatric reference intervals for an integrated clinical chemistry and immunoassay analyzer, Abbott ARCHITECT ci8200

Chan

Seiden‐Long

Aytekin

et al. 2009

Clinical Biochemistry

View full text Add to dashboard Cite

“…Studies in adult patients with PAH have suggested that NT-proBNP (7), norepinephrine (9), and uric acid (11) are correlated with hemodynamic and functional parameters and could be used for monitoring therapy effects and prognosis in these patients. Although appropriate reference values are lacking in children, preliminary data suggest that BNP and NT-proBNP levels are useful in diagnosing and managing pediatric heart failure, congenital heart disease, and cardiac transplantation (12).…”

mentioning

confidence: 99%

Biological Serum Markers in the Management of Pediatric Pulmonary Arterial Hypertension

et al. 2008

View full text Add to dashboard Cite

Appropriate parameters are needed for the monitoring of children with pulmonary arterial hypertension (PAH). Various biologic markers seem to be of use in adults with PAH. No data are available on their value in children with PAH. In this study, the relation between serum markers, functional parameters, and hemodynamic variables in pediatric PAH and their ability to predict survival is determined. Serum N-terminal pro brain natriuretic peptide (NT-proBNP), uric acid, norepinephrine, and epinephrine were measured and correlated with invasive hemodynamics, functional parameters, and outcome in 29 pediatric patients with PAH who visited a tertiary reference center for pediatric PAH between 1997 and 2005. NT-proBNP correlated with functional class (R ϭ 0.36; p ϭ 0.03) and 6-min walking distance (6MWD) (R ϭ Ϫ0.53; p Ͻ 0.001). Uric acid correlated with mean pulmonary arterial pressure, pulmonary vascular resistance, and cardiac index (R ϭ 0.63, p ϭ 0.01; R ϭ 0.71, p ϭ 0.03, and R ϭ Ϫ0.65, p ϭ 0.007, respectively). After initiation of treatment, NT-proBNP decreased. This decrease correlated with an increased 6MWD. Finally, norepinephrine and NT-proBNP levels were highly predictive for mortality. In this series of children with PAH, biologic markers were correlated with hemodynamics and functional capacity, as parameters of disease severity. The data indicate that these markers can be used to monitor treatment effects and predict mortality in pediatric PAH. (Pediatr Res 63: 321-327, 2008) P ulmonary arterial hypertension (PAH) is a chronic, progressive, and usually fatal disease. It is characterized by proliferation of pulmonary vascular cells and obliteration of small pulmonary arteries, leading to increased pulmonary vascular resistance and eventually right heart failure and death. PAH may present at any age, from infancy into high age. In the last decade, new pharmacological therapies have been developed that improve hemodynamics, exercise capacity, and survival in these patients. For optimal clinical decision-making, it has become of growing importance to accurately assess disease severity, effectiveness of therapy, and prognosis in the individual patient with PAH.Several correlates of disease severity and survival have been described in adults with PAH. Hemodynamic and functional capacity parameters are currently the cornerstones in characterizing disease progression. Invasively obtainable hemodynamic parameters have been shown to represent disease severity and to predict survival (1). Noninvasive parameters for functional capacity are used for the assessment of clinical condition, severity of disease, and effectiveness of therapy. Six-min walking distance (6MWD) has been shown to correlate well with World Health Organization (WHO) functional class, and also with hemodynamic parameters (2). Further, maximal cardiopulmonary exercise testing can be safely performed in these patients using specific guidelines, and is used with increasing frequency (3).In pediatric patients with PAH, the use of these paramete...

show abstract

B-type natriuretic peptide in pediatrics

Cited by 32 publications

References 44 publications

Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP

Physiological, pathological, pharmacological, biochemical and hematological factors affecting BNP and NT-proBNP

Canadian Laboratory Initiative on Pediatric Reference Interval Database (CALIPER): Pediatric reference intervals for an integrated clinical chemistry and immunoassay analyzer, Abbott ARCHITECT ci8200

Biological Serum Markers in the Management of Pediatric Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About